FOLR1 and neoplasm: A possible strategy to circumvent on-target off-tumor toxicity is the use of dual targeting/AND-gated CARs requiring binding to both FOLR1 and a hematopoietic cell–specific marker to elicit T cell–mediated killing of tumor cells.